363 related articles for article (PubMed ID: 19346520)
1. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
[TBL] [Abstract][Full Text] [Related]
2. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
[TBL] [Abstract][Full Text] [Related]
3. PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee.
Chalmers J; Neal B; MacMahon S;
J Hypertens Suppl; 2000 May; 18(1):S13-9. PubMed ID: 10939785
[TBL] [Abstract][Full Text] [Related]
4. The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus.
Waeber B; de la Sierra A; Ruilope LM
Am J Cardiovasc Drugs; 2009; 9(5):283-91. PubMed ID: 19791837
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.
Chalmers J; Joshi R; Kengne AP; Ninomiya T; Bi Y; Bompoint S; Billot L; Patel A;
J Hypertens Suppl; 2008 Sep; 26(3):S21-7. PubMed ID: 19363849
[TBL] [Abstract][Full Text] [Related]
6. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
[TBL] [Abstract][Full Text] [Related]
7. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
Du X; Ninomiya T; de Galan B; Abadir E; Chalmers J; Pillai A; Woodward M; Cooper M; Harrap S; Hamet P; Poulter N; Lip GY; Patel A;
Eur Heart J; 2009 May; 30(9):1128-35. PubMed ID: 19282274
[TBL] [Abstract][Full Text] [Related]
8. Consistency of treatment effect of perindopril and indapamide across broad spectrum of vascular disease.
Cardiovasc J Afr; 2009; 20(3):206. PubMed ID: 19575093
[No Abstract] [Full Text] [Related]
9. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
Boos CJ
Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997
[TBL] [Abstract][Full Text] [Related]
10. PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee.
J Hypertens; 1999 Nov; 17(11):1647-55. PubMed ID: 10608480
[TBL] [Abstract][Full Text] [Related]
11. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML
Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685
[TBL] [Abstract][Full Text] [Related]
12. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
[TBL] [Abstract][Full Text] [Related]
13. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
14. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
Brugts JJ; Ferrari R; Simoons ML
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
[TBL] [Abstract][Full Text] [Related]
16. PROGRESS--perindopril protection against recurrent stroke study: status in July 1996. PROGRESS Management Committee.
J Hypertens Suppl; 1996 Dec; 14(6):S47-51. PubMed ID: 9023716
[TBL] [Abstract][Full Text] [Related]
17. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
18. Implications of the ADVANCE study for clinical practice.
Zannad F
J Hypertens Suppl; 2008 Sep; 26(3):S29-32. PubMed ID: 19363850
[TBL] [Abstract][Full Text] [Related]
19. ADVANCE: action in diabetes and vascular disease.
Patel A; Chalmers J; Poulter N
J Hum Hypertens; 2005 Jun; 19 Suppl 1():S27-32. PubMed ID: 16075030
[TBL] [Abstract][Full Text] [Related]
20. [ADVANCE: a morbidity mortality study of diabetes and hypertension].
Heim A; Feihl F; Waeber B
Rev Med Suisse; 2008 Jan; 4(139):28, 30, 32-3. PubMed ID: 18251212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
